Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer. Though the field has a lot of intuitive appeal, harnessing the body's own immune system to fight cancer with the hope of sustained effect and a very mild side effect profile, proven benefits of immunotherapy in cancer have been slow to come. But in the last few years, we've seen new treatments with impressive survival benefits in prostate cancer, melanoma, and others...while in lung cancer, the key studies are being conducted but have yet to report out.
Dr. Govindan covered the big topics of MAGE-A3, Stimuvax, and Lucanix in his part of the program. The audio and video versions of the podcast are below, along with the transcript and figures.
Part 2, featuring Dr. Brahmer, is being edited now and will be available soon. This includes some discussion of the research into the anti-PD1 vaccine that emerged as one of the most exciting stories in lung cancer from ASCO 2012, so look for that here soon.